ArticleJournal of clinical medicine2020
Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Reduction of angiogenesis in chorioallantoic membrane xenografted hepatocellular carcinomas by treatment with a decorin-expressing herpes simplex virus vector.Virology journal · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.Journal of clinical medicine · 2026Review
- Physical Activity Improves Overall Survival in Patients with Hepatocellular Carcinoma.Liver cancer · 2026Article
- Review
- The role of exercise-induced myokines in cancer-associated inflammation and immune regulation: mechanisms and prospects.Frontiers in sports and active living · 2026Review
- Physical Activity, Exerkines, and Their Role in Cancer Cachexia.International journal of molecular sciences · 2025Review
- Integrated analysis reveals key circRNA-mediated regulatory axes related to prognosis and immune infiltration in lung adenocarcinoma.BMC medical genomics · 2025Article
- Review
- The Role of Myokines in Liver Diseases.International journal of molecular sciences · 2025Review
- Mitochondrial dysfunction in age-related sarcopenia: mechanistic insights, diagnostic advances, and therapeutic prospects.Frontiers in cell and developmental biology · 2025Review
- Exerkines and myokines in aging sarcopenia.Frontiers in endocrinology · 2025Review
- Physical Activity as the Best Supportive Care in Cancer: The Clinician's and the Researcher's Perspectives.Cancers · 2022Review
- Review
- Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways.American journal of physiology. Cell physiology · 2022Review
- Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: A multicenter study.Frontiers in oncology · 2022Article
- Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer.Journal of clinical medicine · 2021Article
- Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling.Frontiers in cell and developmental biology · 2021Article
- Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then.Annals of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
The outcome of patients with hepatocellular carcinoma (HCC) is still poor. Decorin is a small leucine-rich proteoglycan, which exerts antiproliferative and antiangiogenic properties in vitro. We aimed to investigate the associations of decorin with physical function and prognosis in patients with HCC. We enrolled 65 patients with HCC treated with transcatheter arterial chemoembolization (median age, 75 years; female/male, 25/40). Serum decorin levels were measured using enzyme-linked immunosorbent assays; patients were classified into the High or Low decorin groups by median levels. Associations of decorin with physical function and prognosis were evaluated by multivariate correlation and Cox regression analyses, respectively. Age and skeletal muscle indices were not significantly different between the High and Low decorin groups. In the High decorin group, the 6-min walking distance was significantly longer than the Low decorin group and was significantly correlated with serum decorin levels (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.